Re: second cancers after adjuvant tamoxifen therapy for breast cancer.
Rutqvist
L E
LE
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000139:chemically induced; D004965:Estrogen Antagonists / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D012306:Risk; D018426:SEER Program; D013629:Tamoxifen / Q000009:adverse effects*; D013997:Time Factors
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen